We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo-controlled trial.
- Authors
Hoyos, Camilla M.; Killick, Roo; Yee, Brendon J.; Grunstein, Ronald R.; Liu, Peter Y.
- Abstract
Study objectives High doses of short-term testosterone have been shown to acutely worsen sleep-disordered breathing in men with obstructive sleep apnoea ( OSA). The effects of lower, near-conventional doses of testosterone in obese men with OSA may differ over the longer term but have not been systematically studied. We assessed sleep and breathing effects of near-conventional testosterone treatment as an adjunct to weight loss in obese men with severe OSA. Design An 18-week randomized, double-blind, placebo-controlled, parallel group trial in 67 men. Interventions All subjects were placed on a hypocaloric diet and then received intramuscular injections of 1000 mg testosterone undecanoate or placebo at 0, 6 and 12 weeks. Measurements and Results Sleep and breathing were measured by nocturnal polysomnography at 0, 7 and 18 weeks. Testosterone, compared to placebo, worsened the oxygen desaturation index ( ODI) by 10·3 events/h (95% CI, 0·8-19·8 events/h; P = 0·03) and nocturnal hypoxaemia (sleep time with oxygen saturation <90%, SpO2T90%) by 6·1% (95% CI, 1·5-10·6; P = 0·01) at 7 weeks. Testosterone therapy did not alter ODI (4·5, −5·4 to 14·4 events/h; P = 0·36) or SpO2T90% at 18 weeks (2·9, −1·9-7·7%; P = 0·23) compared to placebo. The testosterone treatment effects on ODI and SpO2T90% were not influenced by baseline testosterone concentrations (testosterone by treatment interactions, all P > 0·35). Blood testosterone concentrations did not correlate with ODI or SpO2T90% (all P > 0·19). Conclusions Testosterone therapy in obese men with severe OSA mildly worsens sleep-disordered breathing in a time-limited manner, irrespective of initial testosterone concentrations. This time-dependency was not related to testosterone concentrations. Trial Registration www.anzctr.org.au Identifier: ACTRN1260-6000404527.
- Subjects
THERAPEUTIC use of testosterone; OVERWEIGHT men; SLEEP; RESPIRATION; SLEEP apnea syndromes
- Publication
Clinical Endocrinology, 2012, Vol 77, Issue 4, p599
- ISSN
0300-0664
- Publication type
Article
- DOI
10.1111/j.1365-2265.2012.04413.x